Barclays Issues a Buy Rating on Relay Therapeutics (RLAY)
Relay Therapeutics Analyst Ratings
Relay Therapeutics (RLAY) Gets a Buy From Barclays
Relay Therapeutics Upgraded by Barclays Ahead of Data Readout
Relay Therapeutics Analyst Ratings
Barclays Upgrades Relay Therapeutics to Overweight, Maintains Price Target to $15
Optimistic Buy Rating for Relay Therapeutics: Pipeline Progress and Financial Stability Drive Analyst Confidence
Oppenheimer: The Relay Therapeutics (RLAY.US) rating was reaffirmed, and the target price was adjusted from better than market to better than market, and the target price was adjusted from $33.00 to $25.00.
Relay Therapeutics Analyst Ratings
Oppenheimer Reiterates Outperform on Relay Therapeutics, Lowers Price Target to $25
Analysts Are Bullish on These Healthcare Stocks: Relay Therapeutics (RLAY), Kura Oncology (KURA)
Barclays Keeps Their Hold Rating on Relay Therapeutics (RLAY)
Strong Buy Rating for Relay Therapeutics Amid Pipeline Progress and Strategic Direction
Analysts Offer Insights on Healthcare Companies: Korro Bio (KRRO), Relay Therapeutics (RLAY) and Regeneron (REGN)
Relay Therapeutics (RLAY) Gets a Hold From Barclays
Optimistic Buy Rating for Relay Therapeutics: Strong Financial Standing and Strategic Pipeline Focus
Relay Therapeutics Analyst Ratings
Relay Therapeutics Poised for Growth With Promising RLY-2608, Analyst Maintains Buy Rating
Analysts Offer Insights on Healthcare Companies: Kinnate Biopharma (KNTE), Relay Therapeutics (RLAY) and Eyenovia (EYEN)
Relay Therapeutics Analyst Ratings